The FDA approved 22 new drugs in June 2025, tying for the highest monthly total this year and contributing to 107 approvals in the first half of 2025. Notable approvals include Gilead’s twice-yearly HIV prevention shot and Nuvation Bio's ROS1 inhibitor for non-small cell lung cancer. Arvinas and Pfizer filed for approval of the estrogen receptor PROTAC vepdegestrant, and Monte Rosa Therapeutics plans a Phase 1 trial of a NEK7 degrader for inflammatory diseases. Novo Nordisk advances Phase 3 trials for an amylin analog/GLP-1 combination for weight loss, while Altimmune reported positive Phase 2 data for a GLP-1/glucagon dual receptor agonist in MASH. These developments reflect continued momentum in oncology, HIV, and metabolic disease therapeutics.